跳至主要内容
临床试验/CTRI/2022/12/047860
CTRI/2022/12/047860尚未招募3 期

A prospective, randomized, open-label, active-controlled, clinical study to evaluate the tolerability and incidence of pregnancy complications up on Lipocal supplementation in pregnant women

G.C Chemie Pharmie Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Pregnant females between the ages of >=18 and 40 years (both inclusive) willing to participate in study and provide written informed consent.
  • 2. Pregnant women at 20th weeks attending antenatal care visit (ANC) visit at study clinics.

排除标准

  • 1. No medical contraindications to continuing pregnancy.
  • 2. Treatment with antitubercular and anti-epileptic drugs.
  • 3. History of pre-eclampsia & eclampsia
  • 4. History or signs and/or symptoms of nephrolithiasis
  • 5. Prior diagnosis of parathyroid disorder or thyroidectomy
  • 6. Diseases that require digoxin, phenytoin, or tetracycline therapy
  • 7. History of chronic liver disease
  • 8. History of renal disease & no known uterine anomaly
  • 9. No history of cervical conization
  • 10. Obesity (BMI 30.0 and higher)
  • 11. Diagnostic history of Type I & Type II Diabetes
  • 12. Diagnostic history of hypertension
  • 13. History of any autoimmune disease
  • 14. Subject with multiple pregnancy.
  • 15. Diagnostic history of fetal anomalies.
  • 16. Any other condition that in the opinion of the
  • investigator does not justify the patients participation in the study.

研究者

发起方
G.C Chemie Pharmie Limited

相似试验